Targeting DKK1 with a DNA vaccine to prevent development of multiple myeloma
Active Awarded Last action
- Contract number
- 75N91023F00002
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $0
Award facts
- Opportunity
-
- TORFP2023E02 Solicitation number
- Contract value 0% obligated
- $1,249,115.00 Current and potential, with all options
- Completion date 99% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $147,621 | |
| Other Administrative Action | $0 | |
| Original award | $1,101,494 |
About this award
The University of Texas MD Anderson Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center located in Houston, Texas, received a $1.25 million firm fixed-price delivery order from the National Cancer Institute on June 26, 2023, to conduct preclinical research on a DNA vaccine targeting DKK1 (Dickkopf-1) for the prevention of multiple myeloma development. This delivery order falls under the PREVENT Cancer Preclinical Drug Development Program, a $149.995 billion indefinite delivery contract vehicle managed by the National Cancer Institute through January 24, 2029. Under the PREVENT IDIQ framework, MD Anderson evaluates potential cancer preventive agents through preclinical efficacy testing and biomarker evaluation, with this specific task order focused on advancing understanding of DKK1-targeted immunotherapy as a preventive strategy. The contract carries no small business set-aside designation and is scheduled for completion by October 25, 2026.
As a premier academic cancer research institution and component of the University of Texas System, MD Anderson brings extensive multidisciplinary expertise in translational and clinical cancer research to this assignment. The center's established track record includes delivering multiple delivery orders and cooperative agreements under the PREVENT program, such as prior awards for pancreatic cancer prevention through time-restricted feeding and colorectal cancer prevention initiatives, demonstrating institutional competency in executing complex preclinical drug development programs that support the National Cancer Institute's cancer prevention research agenda.
Quick answers
Who was awarded contract 75N91023F00002?
75N91023F00002 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on June 26, 2023.
How much is contract 75N91023F00002 worth?
The government has obligated $0 on 75N91023F00002. Its current value, with exercised options, is $1,249,115.
Is contract 75N91023F00002 an order under another contract?
Yes. 75N91023F00002 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91023F00002 competed?
The extent of competition for 75N91023F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award